Lantis' OCT Dental Imaging System Uses Fast-Growing, Light-Based Technology

DENVILLE, N.J., July 22, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc.'s (Pink
Sheets:LLSR) (www.lantislaser.com) OCT Dental Imaging System, a diagnostic aid
for the early detection of decay and microstructural defects, deploys optical
coherence tomography (OCT), a novel light-based, high-resolution, diagnostic
imaging technology.

According to Optical Coherence Tomography - Technology, Markets, and
Applications: 2008-2012, the first market research report to quantify this
rapidly expanding field, the global market for OCT systems is currently around
$200 million and growing at an annual rate of 34%. This trend is expected to
continue for the next several years, with revenues topping $800 million by
2012.(1)

OCT is fast becoming the most successful optics technology to be applied in the
medical field. As it a light-based technology, unlike x-ray, there is no
radiation. It is generally considered to be the sixth major diagnostic imaging
technology after x-ray, ultrasound, CT scan, MRI and PET scan. The significance
of OCT technology is evidenced by the number of bio-medical applications under
research and development and the large increase in the number of OCT
publications over the last several years.

The increasing interest in OCT in the medical field, of which dentistry is the
largest sub-group comprising 140,000 dentists practicing in 100,000 offices and
clinics in the U.S. alone, has grown significantly over the last few years as is
evidenced by the number of research publications. OCT applications research and
publications are occurring over a wide area of medical disciplines, including
ophthalmology, cardiovascular imaging, dermatology, optical biopsies, cancer
detection, urology, and ear, nose and throat.

OCT was first discovered and researched in the early 1990s at the Massachusetts
Institute of Technology and commercialized in ophthalmology, where it has been
widely embraced, by Carl Zeiss Meditec. In a press release in November 2006 Carl
Zeiss announced that they had sold 6000 Stratus( systems since its introduction
in 2002. Cardiovascular imaging and dentistry are expected to be the next major
clinical applications of OCT technology.

Dr Craig Gimbel, Vice-President Clinical Affairs at Lantis, commented that, "OCT
is ideally suited for use in dentistry as it provides high-resolution, chairside
diagnostic imaging, in real time. Lantis' small handpiece scanner which employs
patented state-of-the art MEMS technology, allows easy access to all parts of
the oral cavity and ensures a user friendly interface with the OCT System." Dr.
Gimbel went on to say that he envisages that the many clinical applications of
OCT in dentistry augurs well for OCT to be successfully embraced by the dental
profession. Market introduction of Lantis' OCT Dental Imaging System is
projected for the first quarter of 2009. The OCT System enables dentists to
detect decay and microstructural defects at an early stage and to deploy
minimally invasive treatment.

(1) G. Smolka, Optical Coherence Tomograph: Technology, Markets, and
Applications 2008-2012, PennWell Corp.,
www.BioOpticsWorld.com/resourcecenter/OCTreport.html

About Lantis Laser

Lantis was formed to commercialize the application of novel technologies in the
dental industry. The criteria for selected products include competitive edge,
exclusivity and large market potential. Lantis is currently in Phase 2 and Phase
3 development, moving through beta systems, product development and application
for FDA clearance and plans to launch the OCT Dental Imaging System(TM) in the
first quarter of 2009. Lantis has exclusive rights to the application of OCT
technology in the field of dentistry under its license Agreements with Lawrence
Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and
AXSUN (exclusive). To find out more about Lantis Laser (LLSR: PK), visit
www.lantislaser.com

Safe Harbor: Statements regarding financial matters in this press release other
than historical facts are "forward-looking statements" within the meaning of
section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The company intends that such statements about
the Company's future expectations, including future revenues and earnings,
technology efficacy and all other forward-looking statements be subject to the
safe harbors created thereby. The Company is a development stage company who
continues to be dependent upon outside capital to sustain its existence. Since
these statements (future operational results and sales) involve risks and
uncertainties and are subject to change at any time, the Company's actual
results may differ materially from expected results.

-0-
CONTACT: Lantis Laser Inc.
Stan Baron, President & CEO
(203) 300-7622
sbaron@lantislaser.com

AGORACOM Investor Relations
http://www.agoracom.com/ir/lantislaser
llsr@agoracom.com

For OCT Updates
http://octnews.hivefire.com